UNSPSC 51312310: Diphenhydramine laurylsulfate

This classification denotes a histamine-1 receptor antagonist and antiemetic agent with the molecular formula C17H21NO.C12H26O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 3E2CN035LB, chemically known as ethanamine, 2-(diphenylmethoxy)-n,n-dimethyl-, dodecyl sulfate, but more generally known as diphenhydramine laurylsulfate, which bears US NIH Compound Identifier 9892949.

European Medicines Agency schedules diphenhydramine laurylsulfate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07211MIG. Most nations, for tariff purposes, schedule diphenhydramine laurylsulfate under HS 29221980. SMILES: CCCCCCCCCCCCOS(=O)(=O)O.CN(C)CCOC(C1CCCCC1)C2CCCCC2.

UNSPSC 51312310 Diphenhydramine laurylsulfate is a Commodity code that maps poorly to the recent state and local opportunities on record. The code nominally describes a single pharmaceutical active ingredient, but recent solicitations under this code actually cover broad pharmaceutical procurement — naloxone and drug deactivation systems, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals with over-the-counter products. The divergence between the code's narrow chemical name and the scope of work being bought suggests either miscoding in the source data or a state and local practice of using this code as a catch-all for pharmaceutical procurement more broadly. State and local buyers include health departments (Seminole County, Florida), state health and human services commissions (Texas HHS), and cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance, serving multiple states including Oregon).

Recent opportunities span Florida, Texas, and Minnesota with multistate reach through cooperative purchasing. Seminole County, Florida issued IFB60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, due July 26, 2023. Texas HHS issued RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs before formal solicitation. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products, due March 26, 2026, with awards effective July 1, 2026 through authorized wholesalers AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson. Without concrete evidence that diphenhydramine laurylsulfate itself is being actively solicited under this code, treating this as a quiet code may be more accurate than forcing fit to the recent opportunities.